NICE

News

NICE clears NHS use of Roche's Tecentriq in bladder cancer

NICE has recommended routine NHS access to Roche's cancer immunotherapy Tecentriq for some bladder cancer patients, four years after it was first made available via the Cancer Drugs Fund (C

News

Keytruda backed by NICE for late-stage oesophageal cancer

MSD's Keytruda has become the first immunotherapy cleared by NICE for previously-untreated patients with advanced oesophageal cancer, making it an option for routine NHS treatment.

News

NICE backs BioCryst's Orladeyo for hereditary angioedema

BioCryst Pharma's Orladeyo has been recommended by NICE as a treatment for the rare disease hereditary angioedema (HAE) in England, Wales and Northern Ireland.

News

NICE changes its mind on J&J's Erleada in prostate cancer

NICE has reversed its position on Johnson & Johnson's oral prostate cancer therapy Erleada in patients with hormone-relapsed or hormone sensitive tumours, backing NHS use of the drug.

News

NICE backs Cosentyx' use in thousands of children with psori...

NICE has recommended broadening NHS use of Novartis' IL-17 inhibitor Cosentyx to include children aged six to 17 with severe plaque psoriasis.

News

NICE backs NHS use of Novartis' cholesterol drug Leqvio

Novartis' cholesterol-lowering drug Leqvio will be made available on the NHS in England and Wales, and could help to prevent up to 30,000 deaths, according to NICE.